157 related articles for article (PubMed ID: 35418463)
1. Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease.
Myers PS; O'Donnell JL; Jackson JJ; Lessov-Schlaggar CN; Miller RL; Foster ER; Cruchaga C; Benitez BA; Kotzbauer PT; Perlmutter JS; Campbell MC
Neurology; 2022 Jul; 99(1):e66-e76. PubMed ID: 35418463
[TBL] [Abstract][Full Text] [Related]
2. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
[TBL] [Abstract][Full Text] [Related]
3. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.
Shahid M; Kim J; Leaver K; Hendershott T; Zhu D; Cholerton B; Henderson VW; Tian L; Poston KL
Neurobiol Dis; 2019 Jul; 127():278-286. PubMed ID: 30826425
[TBL] [Abstract][Full Text] [Related]
4. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.
Jack CR; Wiste HJ; Therneau TM; Weigand SD; Knopman DS; Mielke MM; Lowe VJ; Vemuri P; Machulda MM; Schwarz CG; Gunter JL; Senjem ML; Graff-Radford J; Jones DT; Roberts RO; Rocca WA; Petersen RC
JAMA; 2019 Jun; 321(23):2316-2325. PubMed ID: 31211344
[TBL] [Abstract][Full Text] [Related]
5. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia.
Gomperts SN; Locascio JJ; Rentz D; Santarlasci A; Marquie M; Johnson KA; Growdon JH
Neurology; 2013 Jan; 80(1):85-91. PubMed ID: 23243071
[TBL] [Abstract][Full Text] [Related]
6. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
[TBL] [Abstract][Full Text] [Related]
8. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
[TBL] [Abstract][Full Text] [Related]
9. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline.
Bucci M; Chiotis K; Nordberg A;
Mol Psychiatry; 2021 Oct; 26(10):5888-5898. PubMed ID: 34593971
[TBL] [Abstract][Full Text] [Related]
12. Predicting future rates of tau accumulation on PET.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Vemuri P; Mielke MM; Whitwell J; Josephs K; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
Brain; 2020 Oct; 143(10):3136-3150. PubMed ID: 33094327
[TBL] [Abstract][Full Text] [Related]
13. Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1.
Buongiorno M; Antonelli F; Compta Y; Fernandez Y; Pavia J; Lomeña F; Ríos J; Ramírez I; García JR; Soler M; Cámara A; Fernández M; Basora M; Salazar F; Sanchez-Etayo G; Valldeoriola F; Barrio JR; Marti MJ
J Alzheimers Dis; 2017; 55(3):1261-1272. PubMed ID: 27814297
[TBL] [Abstract][Full Text] [Related]
14. Proteinopathy and longitudinal changes in functional connectivity networks in Parkinson disease.
Campbell MC; Jackson JJ; Koller JM; Snyder AZ; Kotzbauer PT; Perlmutter JS
Neurology; 2020 Feb; 94(7):e718-e728. PubMed ID: 31852813
[TBL] [Abstract][Full Text] [Related]
15. Evolution and Predictive Role of Plasma Alzheimer's Disease-related Pathological Biomarkers in Parkinson's Disease.
Lin J; Ou R; Li C; Hou Y; Zhang L; Wei Q; Liu K; Jiang Q; Yang T; Xiao Y; Pang D; Zhao B; Chen X; Yang J; Shang H
J Gerontol A Biol Sci Med Sci; 2023 Dec; 78(12):2203-2213. PubMed ID: 37560912
[TBL] [Abstract][Full Text] [Related]
16. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease.
Pagano G; De Micco R; Yousaf T; Wilson H; Chandra A; Politis M
Neurology; 2018 Sep; 91(10):e894-e905. PubMed ID: 30089615
[TBL] [Abstract][Full Text] [Related]
17. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.
Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266
[TBL] [Abstract][Full Text] [Related]
18. Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction.
Düzel E; Ziegler G; Berron D; Maass A; Schütze H; Cardenas-Blanco A; Glanz W; Metzger C; Dobisch L; Reuter M; Spottke A; Brosseron F; Fliessbach K; Heneka MT; Laske C; Peters O; Priller J; Spruth EJ; Ramirez A; Speck O; Schneider A; Teipel S; Kilimann I; Jens W; Schott BH; Preis L; Gref D; Maier F; Munk MH; Roy N; Ballarini T; Yakupov R; Haynes JD; Dechent P; Scheffler K; Wagner M; Jessen F
Brain; 2022 May; 145(4):1473-1485. PubMed ID: 35352105
[TBL] [Abstract][Full Text] [Related]
19. Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
Tan CH; Fan CC; Mormino EC; Sugrue LP; Broce IJ; Hess CP; Dillon WP; Bonham LW; Yokoyama JS; Karch CM; Brewer JB; Rabinovici GD; Miller BL; Schellenberg GD; Kauppi K; Feldman HA; Holland D; McEvoy LK; Hyman BT; Bennett DA; Andreassen OA; Dale AM; Desikan RS;
Acta Neuropathol; 2018 Jan; 135(1):85-93. PubMed ID: 29177679
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
